| Literature DB >> 23986753 |
Cindy-Love Tremblay1, Audrey Charlebois, Luke Masson, Marie Archambault.
Abstract
Ampicillin-resistant Enterococcus faecium (ARE) has rapidly emerged worldwide and is one of the most important nosocomial pathogens. However, very few reports are available on ARE isolates from canine clinical cases. The objective of this study was to characterize ARE strains of canine clinical origin from a veterinary teaching hospital in Canada and to compare them with human strains. Ten ARE strains from dogs and humans were characterized by multilocus sequence typing (MLST), pulsed field gel electrophoresis (PFGE), antibiotic susceptibility and biofilm activities, presence of rep-families, CRISPR-cas and putative virulence genes. All ARE strains (n = 10) were resistant to ciprofloxacin and lincomycin. Resistances to tetracycline (n = 6), macrolides (n = 6), and to high concentrations of gentamicin, kanamycin and streptomycin (n = 5) were also observed. Canine ARE isolates were found to be susceptible to vancomycin whereas resistance to this antibiotic was observed in human strains. Ampicillin resistance was linked to PBP5 showing mutations at 25 amino acid positions. Fluoroquinolone resistance was attributable to ParC, GyrA, and GyrB mutations. Data demonstrated that all canine ARE were acm (collagen binding protein)-positive and that most harbored the efaAfm gene, encoding for a cell wall adhesin. Biofilm formation was observed in two human strains but not in canine strains. Two to five rep-families were observed per strain but no CRISPR sequences were found. A total of six STs (1, 18, 65, 202, 205, and 803) were found with one belonging to a new ST (ST803). These STs were identical or closely related to human hospital-associated lineages. This report describes for the first time the characterization of canine ARE hospital-associated strains in Canada and also supports the importance of prudent antibiotic use in veterinary medicine to avoid zoonotic spread of canine ARE.Entities:
Keywords: Enterococcus faecium; MLST; antibiotic resistance; clinical cases; community-associated; hospital-associated; plasmid; virulence
Year: 2013 PMID: 23986753 PMCID: PMC3750202 DOI: 10.3389/fmicb.2013.00245
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Characterization of .
| 07-5598 | D | Wound | CHL, CIP, ERY, GEN, KAN, LIN, AMP, PEN, STR, TET, TYL | 2, 11, 18 | A1 | 202 | 1 | 1 | 1 | 1 | 1 | 7 | 1 | |||
| M2971-08 | D | Wound | CIP, ERY, GEN, KAN, LIN, AMP, PEN, STR, TET, TYL | 2, 6, 11 | A2 | 202 | 1 | 1 | 1 | 1 | 1 | 7 | 1 | |||
| M2146-08 | D | Bile | CIP, LIN, AMP, PEN, TET | 2, 6, 11, 14 | E1 | 803 | 1 | 1 | 1 | 1 | 1 | 57 | 1 | |||
| M5853-09 | D | Urine | CIP, LIN, AMP, PEN, TET | 2, 6, 11, 14 | E2 | 803 | 1 | 1 | 1 | 1 | 1 | 57 | 1 | |||
| M20638-11 | D | Urine | CIP, LIN, AMP, PEN | 6, 11, 14 | F | 803 | 1 | 1 | 1 | 1 | 1 | 57 | 1 | |||
| CCRI-18581 | H | Anal | CIP, ERY, KAN, LIN, AMP, PEN, STR, TET, TYL, VAN | 11, 14, 17, Unique | H | 18 | 7 | 1 | 1 | 1 | 5 | 1 | 1 | |||
| CCRI-16354 | H | Rectal | CIP, LIN, AMP, PEN, VAN | 1, 2, 14 | B | 18 | 7 | 1 | 1 | 1 | 5 | 1 | 1 | |||
| CCRI-16717 | H | Stools | CIP, ERY, GEN, KAN, LIN, AMP, NIT, STR, TET, TYL, VAN | 1, 2, 4, 6, 11 | D | 1 | 8 | 4 | 5 | 7 | 1 | 1 | 5 | |||
| CCRI-18707 | H | Pus | CIP, ERY, GEN, KAN, LIN, AMP, PEN, STR, TYL | 17, Unique | C | 65 | 1 | 2 | 1 | 20 | 1 | 1 | 9 | |||
| CCRI-18231 | H | Wound | CIP, ERY, GEN, KAN, LIN, AMP, PEN, STR, TYL | 17, Unique | G | 205 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | |||
D, dogs; H, humans.
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; GEN, gentamicin; KAN, kanamycin; LIN, lincomycin; NIT, nitrofurantoin; PEN, penicillin; STR, streptomycin; TET, tetracycline; TYL, tylosin; VAN, vancomycin.
Identified by microarray; aac(6′)-Ii is intrinsic resistance in E. faecium.
Weak biofilm producer (+) and strong biofilm producer (+++), based upon the previously calculated OD values (see Materials and Methods)
Primers and conditions used in PCR for confirmation of microarray results and for .
| F-GTGGACAAAGGTACAACGAG | 406 | 55 | De Leener et al., | |
| R-CGGTAAAGTTCGTCACACAC | ||||
| tet( | F-GATGGCATACAGGCACAGAC | 614 | 62 | Aarestrup, |
| R-CAATATCACCAGAGCAGGCT | ||||
| F-ATAAATTGTTTCGGGTCGGTAAT | 1077 | 52 | De Leener et al., | |
| R-AACCAGCCAACTAATGACAAGT | ||||
| F-GAAAAGRTACTCAACCAAATA | 639 | 52 | Poeta et al., | |
| R-AGTAACGGTACTTAAATTGTTTAC | ||||
| F-GGTGCCACAATCAAATTAGG | 380 | 46 | Seno et al., | |
| R-GATTCTTCGATTGTGTTGTAAACG | ||||
| F-TTGCTAATGCTAGTCCACGACC | 955 | 63 | Seno et al., | |
| R-GCGTCAACACTTGCATTGCCGAA | ||||
| 1 (pIP501) | F-TCGCTCAATCACTACCAAGC | 624 | 52 | X17655 |
| R-CTTGAACGAGTAAAGCCCTT | ||||
| 9 (pCF10) | F-GCTCGATCARTTTTCAGAAG | 201 | AY855841 | |
| R-CGCAAACATTTGTCWATTTCTT | ||||
| 4 (pMBB1) | F-ACTATGTCGTTGAGTCTAATGACT | 430 | 52 | U26268 |
| R-AGCAAGATAGAATATTTACTTTTAAGTTT | ||||
| 14 (pRI1) | F-RTTTTGRCTTTCTTSYTTCA | 164 | EU327398 | |
| R-TGAAAGYTTRGATAGYTTTGC | ||||
| 17 (pRUM) | F-TACTAACTGTTGGTAATTCGTTAAAT | 502 | EU376117 | |
| R-ATCAAGGACTCAACCGTAATT | ||||
| Unique (pMG1/pHTβ) | F-GTATTAACACACTGGACTC | 199 | 52 | AB206333 |
| R-TCAGTGTAGGCAATAACCC | ||||
| 2 (pRE25) | F-GAGAACCATCAAGGCGAAAT | 630 | 56 | X92945 |
| R-ACCAGAATAAGCACTACGTACAATCT | ||||
| 6 (pS86) | F-ACGAATGAAAGATAAAGGAGTAG | 551 | AJ223161 | |
| R-TAAATTCTAGTTTGGCAATCTTAT | ||||
| 8 (pAM373) | F-CCAATCATGTAATGTTACAACC | 394 | AE002565 | |
| R-TAGATACGACAAAAGAAGAATTACA | ||||
| 18 (pEF418) | F-ACACCAGTCGAAATGAATTT | 462 | AF408195 | |
| R-AGGAATATCAAGTAATTCATGAAAGT | ||||
| 13 (pC194) | F-TACCAGAATAYTTAGCCATTTC | 402 | 54 | V01277 |
| R-ATGATGCAATATATTAAGCA | ||||
| 15 (pUSA03) | F-CAGTAGAAGAAAATTATAAAGAAC | 327 | CP000258 | |
| R-GTTATGGCTGGTTTTAATAAA | ||||
| 16 (pSAS) | F-CTTCTATATCACTATCATTGTCATT | 592 | BX571858 | |
| R-CAGGAAAACACTTCGTTTAT | ||||
| 11 (pEF1071) | F-TCTAGAATGCGTGAAAAAGG | 500 | 54 | AF164559 |
| R-CCTTTGAAGATWGCRGTWAG |
Rep-family numbers are associated with plasmid in parenthesis.
F, forward; R, reverse.
Antibiotic resistance of .
.
.
Mutations in .
| 4 | M2146-08 | D | None | None | None |
| 8 | M5853-09 | D | None | None | None |
| 8 | CCRI-16717 | H | None | None | None |
| 64 | M20638-11 | D | I (83) | N (436) | R (80) |
| 128 | 07-5598 | D | Y (83), W (127) | None | I (80) |
| 128 | CCRI-18231 | H | K (87) | None | I (80), D (73) |
| >256 | M2971-08 | D | Y (83) | None | I (80) |
| >256 | CCRI-18581 | H | Y (83) | None | R (80) |
| >256 | CCRI-16354 | H | Y (83) | W (371), S (455) | I (80) |
| >256 | CCRI-18707 | H | R (83) | None | I (80) |
D, dogs; H, humans.
D, aspartic acid; I, isoleucine; K, lysine; N, asparagine; R, arginine; S, serine; W, tryptophan; Y, tyrosine.
Amino acid changes detected in the C- and N-terminal regions of .
| − | − | X84860 | G | A | E | E | K | T | L | D | A | T | G | Q | − | H | A | M | N | F | A | E | V | A | E | D | − |
| 256 | D | 07-5598 | NA | NA | Q | M | V | A | D | 1 | |||||||||||||||||
| >256 | D | M2971-08 | NA | NA | Q | M | V | A | D | 1 | |||||||||||||||||
| >256 | H | CCRI-18581 | NA | Q | M | V | A | NA | 1 | ||||||||||||||||||
| >256 | D | M2146-08 | NA | Q | A | F | A | 2 | |||||||||||||||||||
| >256 | D | M5853-09 | NA | Q | A | F | A | D | 2 | ||||||||||||||||||
| >256 | D | M20638-11 | NA | G | Q | A | F | A | D | 2 | |||||||||||||||||
| 64 | H | CCRI-16717 | NA | NA | E | D | Q | − | A | M | F | V | A | E | D | 3 | |||||||||||
| >256 | H | CCRI-16354 | NA | − | A | F | A | D | 4 | ||||||||||||||||||
| 256 | H | CCRI-18707 | − | A | F | A | NA | 4 | |||||||||||||||||||
| 256 | H | CCRI-18231 | NA | NA | Q | − | A | F | D | 5 | |||||||||||||||||
NA, The sequence at this position was not available.
D, dogs; H, humans.
A, alanine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; K, lysine; L, leucine; M, methionine; N, asparagine; Q, glutamine; S, serine; T, threonine; V, valine.
Amino acid changes with respect to the reference sequence (GenBank accession no. X84860) are indicated in bold.
Alleles were designated 1–5 based on important amino acid substitutions in the C-terminal region.